MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
GLOW Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Glow is a compounded multi-peptide blend marketed for skin rejuvenation that typically combines GHK-Cu, BPC-157, and TB-500 (thymosin beta-4 fragment) in a single subcutaneous injection. The rationale stacks GHK-Cu's collagen, elastin, and proteoglycan stimulation with BPC-157's angiogenic and cytoprotective effects and TB-500's actin-binding, cell-migration, and wound-healing activity, on the hypothesis that the three peptides target complementary phases of dermal remodeling. People study Glow for facial skin quality, hair density, post-procedure recovery, and overall connective-tissue tone [PMID: 30041975][PMID: 27036373]. None of the three components is FDA-approved for cosmetic or dermatologic use, and the blend itself has no controlled human trial data; all clinical evidence is anecdotal or extrapolated from individual peptide studies. Sourcing through compounding pharmacies has tightened sharply under the 2023 to 2025 FDA restrictions on research peptides.
Reconstitute: Add 3 mL bacteriostatic water → 23.3 mg/mL concentration.
Easy measuring: At 23.3 mg/mL, 1 unit = 0.01 mL = 0.233 mg (233 mcg) on a U-100 insulin syringe.
Storage: Lyophilized vials frozen; reconstituted solutions refrigerated; use within 4 weeks.
Compounded blend, not a drug: Glow has no monograph, no standardized ratio, and no clinical trials. Each compounding pharmacy formulates its own mix, and concentrations of GHK-Cu, BPC-157, and TB-500 vary substantially between providers.
Sourcing risk after 503A restrictions: BPC-157 and TB-500 were moved off the FDA bulks list and effectively excluded from 503A compounding by 2024. Most current Glow products are research-chemical-grade with no quality oversight.
Stacked-effect rationale: Theoretical synergy: GHK-Cu drives matrix synthesis, BPC-157 supports angiogenesis and gut-axis healing, TB-500 promotes cell migration and actin remodeling. None of these specific synergies has been clinically demonstrated for skin endpoints.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall to minimize foaming.
Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
Inject slowly over 2–3 seconds and wait a few seconds before withdrawing the needle to ensure complete delivery.
Inject slowly over 2–3 seconds; do not aspirate for subcutaneous injections.
Interactive GLOW Syringe Calculator
Currently visualizing the 70 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 70mg dry powder in 3mL water yields 23.33 mg/mL. To evaluate a 250mcg dose, pull to 1.1 units (1 syringe ticks).
U-100 Syringe Representation
1.1 Units (1 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2,330 mcg | 10 units (0.10 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 70 mg vial.
Peptide Vials (GLOW Blend, 70 mg each):
- check4 weeks (28 days): 1 vial
Insulin Syringes (U-100, preferably 0.3 mL / 30-unit for precision):
- check4 weeks: 28 syringes (1 per day)
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check4 weeks (1 vial): 3 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- check4 weeks: 56 swabs (2 per day) → recommend 1 × 100-count box
Mechanism of Action (MOA)
The GLOW blend brings together three peptides with overlapping but mechanistically distinct regenerative effects. The first component, BPC-157 (Body Protection Compound 157), is a synthetic fifteen-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein found in human gastric juice. In rodent studies, BPC-157 accelerates healing of tendon, ligament, muscle, gut, and skin injuries; promotes angiogenesis through VEGFR2 upregulation; modulates nitric oxide synthase activity; and exerts anti-inflammatory effects on the gut-brain axis. Although clinical trials in humans are essentially absent, BPC-157 has become one of the most widely used research peptides for soft tissue recovery [1]. The second component, TB-500, is a synthetic fragment (often the 17-amino-acid Thymosin Beta-4 active site, sometimes the full-length 43-amino-acid Tβ4) that recapitulates the cell-migration and actin-binding activities of endogenous Thymosin Beta-4. Thymosin Beta-4 is the most abundant intracellular actin-sequestering peptide and is released into wounds where it promotes endothelial cell migration, angiogenesis, hair follicle stem cell activation, and resolution of inflammation through downregulation of NF-κB signaling. Clinical trials of full-length Thymosin Beta-4 have evaluated wound healing in venous stasis ulcers, epidermolysis bullosa, and corneal injuries [2]. The third component, GHK-Cu, is the copper-binding tripeptide described above. It contributes gene-expression modulation, antioxidant enzyme activation, collagen and proteoglycan synthesis, and angiogenesis. GHK-Cu provides a copper-delivery mechanism that complements the actin-mobilizing and trophic actions of the other two peptides [3]. Mechanistically, the rationale for combining these three peptides is convergent stimulation of regenerative pathways: BPC-157 promotes capillary sprouting and tendon/ligament repair, TB-500 mobilizes progenitor cells and supports endothelial migration, and GHK-Cu drives matrix synthesis and gene-level rejuvenation. Together, they are claimed to enhance skin and hair quality, accelerate recovery from cosmetic procedures (laser resurfacing, microneedling), and modulate systemic inflammation. There are, however, no published randomized human trials of the fixed GLOW combination, and all evidence is extrapolated from individual peptide studies, animal models, and clinical experience. Research subcutaneous dosing for GLOW is typically expressed in micrograms of each component per injection. A common protocol from a 10/10/50 mg vial reconstituted in three milliliters of bacteriostatic water delivers roughly 333 micrograms of BPC-157, 333 micrograms of TB-500, and 1.66 mg of GHK-Cu per 0.1 mL injection. Frequency ranges from once daily during loading phases to two or three times weekly during maintenance. Injection is most often into the abdominal subcutaneous tissue using an insulin syringe. Some clinicians administer the blend into specific areas (e.g., periorally, perioribital) to target localized aesthetic concerns, although tissue-specific advantages of local injection have not been demonstrated. As with all unapproved peptide blends, sterility, dosing accuracy, and purity vary widely across suppliers.
Clinical Trial Efficacy Highlights
- starSikiric and colleagues have published a large body of preclinical work on BPC-157 documenting accelerated healing of transected Achilles tendons, gastric ulcers, colitis, muscle crush injuries, and skin wounds in rodents through angiogenic and cytoprotective mechanisms; effects are robust in animal models but human clinical trials remain limited, leaving the BPC-157 contribution to GLOW supported primarily by preclinical evidence [1].
- starGoldstein and colleagues conducted Phase II trials of full-length Thymosin Beta-4 in patients with venous stasis ulcers and epidermolysis bullosa, demonstrating accelerated wound closure with favorable safety profiles, providing the closest available clinical evidence for the TB-500 component of GLOW although the synthetic fragment used in research blends has not undergone identical trials [2].
- starPickart and Margolina's comprehensive 2018 review documents GHK-Cu's wound-healing, anti-inflammatory, antioxidant, and gene-expression effects, supplying the most extensive evidence base of the three GLOW components and supporting its inclusion in skin- and hair-focused regenerative protocols [3].
- starCompounding-pharmacy and clinic-reported case series describe improvements in skin texture, hair density, scar appearance, and post-procedure recovery in patients receiving GLOW combinations, but these reports are unblinded, lack control groups, and are subject to selection and publication bias.
- starAnimal models combining Thymosin Beta-4 and copper peptides report additive or modestly synergistic effects on wound closure, angiogenesis, and collagen deposition, providing mechanistic plausibility for the GLOW blend rationale even in the absence of head-to-head comparisons with the individual peptides [2].
- starNo randomized controlled trials have evaluated the fixed GLOW formulation in any indication, and regulatory authorities have not approved any of the three components for use in compounded blends; clinical decision-making therefore relies entirely on extrapolation from individual peptide research and practitioner experience.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningLocalized injection-site reactions including erythema, swelling, mild pain, bruising, and transient itching are the most common adverse effects, particularly because the copper-peptide component can produce a blue-green tint at the injection site.
- warningSystemic effects reported with the individual components include mild flushing, transient fatigue, light-headedness, and occasional gastrointestinal upset; data specific to the combined blend are sparse.
- warningAllergic or hypersensitivity reactions are rare but possible, especially in individuals with known copper sensitivity (GHK-Cu) or sensitivity to peptide excipients; severe reactions require discontinuation and medical evaluation.
- warningSterile injection technique is essential; cutaneous abscess, cellulitis, and bloodborne infection are real risks with self-administration of unregulated compounded peptide blends.
- warningLong-term safety has not been characterized, and theoretical concerns include effects on angiogenesis in the context of occult malignancy, since BPC-157, TB-500, and GHK-Cu all promote vascular growth and tissue regeneration.
- warningGLOW should be avoided in pregnancy, lactation, active cancer, and known hypersensitivity to any component; medical supervision is strongly advised given the unapproved status of the blend.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical GLOW dosage?expand_more
Research subcutaneous protocols using a 10/10/50 mg vial (BPC-157/TB-500/GHK-Cu) reconstituted in 3 mL of bacteriostatic water typically deliver 250–500 mcg BPC-157, 250–500 mcg TB-500, and 1–2 mg GHK-Cu per injection, administered two to five times weekly for several weeks.
How is GLOW administered?expand_more
GLOW is administered by small-volume subcutaneous injection, usually into the abdomen, with an insulin syringe after reconstitution. Some protocols administer the blend locally near treated tissues (skin lesions, joints) but evidence for local versus systemic superiority is lacking.
Can GLOW be combined with other compounds?expand_more
GLOW is sometimes combined with topical retinoids, peptide serums, microneedling, or platelet-rich plasma in aesthetic protocols. Stacking with additional injectable peptides increases the unstudied combinatorial risk and should only be undertaken under qualified medical supervision.
What are the side effects of GLOW?expand_more
Most reported effects are localized injection-site reactions including redness, swelling, bruising, and blue-green discoloration from the copper peptide. Mild systemic effects (fatigue, flushing) and rare hypersensitivity reactions are possible. Long-term safety is uncharacterized.
Is GLOW FDA approved?expand_more
No. None of the three components (BPC-157, TB-500, GHK-Cu) are FDA approved, and the GLOW blend has not been evaluated by any regulatory authority. It is sold for research use only or through compounding pharmacies in jurisdictions where this is permitted.
Academic References & Study Citations
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. View Scientific Paper →
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. View Scientific Paper →
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. View Scientific Paper →
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View Scientific Paper →
Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. View Scientific Paper →
Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. View Scientific Paper →
Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157's effect on healing. J Physiol Paris. 1997;91(3-5):173-178. View Scientific Paper →
Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. View Scientific Paper →
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. View Scientific Paper →